Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 10 | 2022 | 113 | 3.430 |
Why?
|
| Sarcoma, Kaposi | 7 | 2023 | 52 | 3.060 |
Why?
|
| Registries | 12 | 2021 | 89 | 2.740 |
Why?
|
| Neoplasms | 10 | 2024 | 141 | 2.660 |
Why?
|
| Papillomavirus Infections | 4 | 2021 | 72 | 2.120 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2023 | 32 | 1.610 |
Why?
|
| HIV Infections | 14 | 2024 | 4946 | 1.500 |
Why?
|
| Incidence | 15 | 2022 | 655 | 1.240 |
Why?
|
| Humans | 42 | 2024 | 14077 | 1.070 |
Why?
|
| Female | 29 | 2024 | 8751 | 1.060 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 14 | 1.030 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 12 | 1.000 |
Why?
|
| Male | 26 | 2024 | 6489 | 0.990 |
Why?
|
| Papillomaviridae | 3 | 2019 | 33 | 0.980 |
Why?
|
| Mortality | 4 | 2021 | 101 | 0.960 |
Why?
|
| South Africa | 30 | 2024 | 7312 | 0.930 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 37 | 0.930 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 47 | 0.900 |
Why?
|
| Adult | 17 | 2024 | 5664 | 0.830 |
Why?
|
| Smoking | 2 | 2021 | 99 | 0.790 |
Why?
|
| Alcoholism | 1 | 2021 | 17 | 0.790 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 29 | 0.730 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 186 | 0.720 |
Why?
|
| Young Adult | 11 | 2024 | 2357 | 0.670 |
Why?
|
| Adolescent | 11 | 2024 | 2858 | 0.630 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 10 | 0.630 |
Why?
|
| Case-Control Studies | 5 | 2023 | 464 | 0.630 |
Why?
|
| Middle Aged | 12 | 2024 | 3425 | 0.620 |
Why?
|
| Developing Countries | 4 | 2020 | 385 | 0.620 |
Why?
|
| Anti-Retroviral Agents | 3 | 2023 | 542 | 0.610 |
Why?
|
| Aged | 8 | 2023 | 1650 | 0.590 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 247 | 0.570 |
Why?
|
| Electronic Health Records | 1 | 2015 | 10 | 0.500 |
Why?
|
| Population Surveillance | 2 | 2016 | 325 | 0.480 |
Why?
|
| Child | 8 | 2022 | 2180 | 0.400 |
Why?
|
| Esophageal Neoplasms | 2 | 2023 | 26 | 0.390 |
Why?
|
| Life Style | 2 | 2022 | 80 | 0.390 |
Why?
|
| Melanoma | 2 | 2022 | 8 | 0.380 |
Why?
|
| Risk Factors | 6 | 2022 | 1431 | 0.370 |
Why?
|
| Zimbabwe | 2 | 2022 | 115 | 0.360 |
Why?
|
| Child, Preschool | 5 | 2020 | 1675 | 0.360 |
Why?
|
| Sex Distribution | 3 | 2021 | 89 | 0.340 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 449 | 0.340 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 128 | 0.330 |
Why?
|
| Time Factors | 4 | 2020 | 503 | 0.330 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1377 | 0.330 |
Why?
|
| Carcinoma | 2 | 2018 | 9 | 0.320 |
Why?
|
| Africa South of the Sahara | 4 | 2022 | 328 | 0.320 |
Why?
|
| Infant | 4 | 2020 | 2145 | 0.320 |
Why?
|
| HIV Seropositivity | 2 | 2023 | 263 | 0.320 |
Why?
|
| Age Factors | 3 | 2020 | 364 | 0.310 |
Why?
|
| Prognosis | 3 | 2018 | 197 | 0.310 |
Why?
|
| Age Distribution | 2 | 2021 | 106 | 0.310 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 100 | 0.290 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 48 | 0.270 |
Why?
|
| Pregnancy | 2 | 2022 | 1815 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 168 | 0.260 |
Why?
|
| Cohort Studies | 4 | 2022 | 939 | 0.240 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 2 | 0.230 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 10 | 0.230 |
Why?
|
| Infant, Newborn | 3 | 2017 | 1410 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 190 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2022 | 43 | 0.200 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 27 | 0.200 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 21 | 0.200 |
Why?
|
| Parity | 1 | 2021 | 19 | 0.200 |
Why?
|
| Survival Rate | 2 | 2018 | 96 | 0.190 |
Why?
|
| Neuroblastoma | 1 | 2021 | 5 | 0.190 |
Why?
|
| Machine Learning | 1 | 2021 | 19 | 0.190 |
Why?
|
| Confidence Intervals | 1 | 2021 | 26 | 0.190 |
Why?
|
| Logistic Models | 1 | 2021 | 252 | 0.190 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 14 | 0.180 |
Why?
|
| Regression Analysis | 1 | 2021 | 131 | 0.180 |
Why?
|
| Ribosomal Proteins | 1 | 2019 | 3 | 0.170 |
Why?
|
| Receptors, Laminin | 1 | 2019 | 6 | 0.170 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 61 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 17 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 52 | 0.170 |
Why?
|
| Odds Ratio | 1 | 2019 | 132 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 4 | 0.160 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2018 | 4 | 0.160 |
Why?
|
| Vaginal Smears | 1 | 2018 | 34 | 0.160 |
Why?
|
| Prevalence | 1 | 2021 | 1149 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 59 | 0.150 |
Why?
|
| Mass Screening | 1 | 2019 | 242 | 0.150 |
Why?
|
| Vaccination | 1 | 2019 | 347 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 367 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 4 | 0.130 |
Why?
|
| Global Health | 1 | 2017 | 183 | 0.130 |
Why?
|
| Program Development | 1 | 2015 | 32 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2015 | 89 | 0.120 |
Why?
|
| Sex Factors | 1 | 2015 | 224 | 0.120 |
Why?
|
| HIV-1 | 1 | 2023 | 1239 | 0.120 |
Why?
|
| Child Health Services | 1 | 2012 | 33 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2015 | 767 | 0.100 |
Why?
|
| Meningitis, Meningococcal | 1 | 2010 | 17 | 0.090 |
Why?
|
| Play and Playthings | 1 | 2009 | 3 | 0.090 |
Why?
|
| Paint | 1 | 2009 | 3 | 0.090 |
Why?
|
| Neisseria meningitidis | 1 | 2010 | 36 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 265 | 0.090 |
Why?
|
| Environmental Pollutants | 1 | 2009 | 16 | 0.090 |
Why?
|
| Lead | 1 | 2009 | 33 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2021 | 654 | 0.080 |
Why?
|
| Prostate | 2 | 2018 | 4 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 194 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2017 | 1275 | 0.080 |
Why?
|
| Genotype | 2 | 2019 | 430 | 0.070 |
Why?
|
| Diagnostic Services | 1 | 2024 | 3 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2023 | 103 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 104 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2022 | 3 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 13 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2021 | 4 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 2 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 77 | 0.050 |
Why?
|
| Medical Record Linkage | 1 | 2021 | 6 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2021 | 64 | 0.050 |
Why?
|
| Human Development | 1 | 2020 | 3 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2023 | 1131 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 68 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 70 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 149 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 4 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 10 | 0.040 |
Why?
|
| Patents as Topic | 1 | 2019 | 18 | 0.040 |
Why?
|
| Drug Design | 1 | 2019 | 28 | 0.040 |
Why?
|
| Data Collection | 1 | 2020 | 86 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 154 | 0.040 |
Why?
|
| Penile Neoplasms | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 6 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 4 | 0.040 |
Why?
|
| Baltimore | 1 | 2018 | 5 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 360 | 0.040 |
Why?
|
| HIV | 1 | 2021 | 380 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 170 | 0.040 |
Why?
|
| Income | 1 | 2018 | 83 | 0.040 |
Why?
|
| Genomics | 1 | 2018 | 106 | 0.040 |
Why?
|
| Animals | 1 | 2019 | 1063 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 37 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 6 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 405 | 0.030 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2009 | 2 | 0.020 |
Why?
|
| Bacteremia | 1 | 2010 | 79 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 110 | 0.020 |
Why?
|